Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Lantana Consulting Group, Atlanta, Georgia.
JAMA. 2021 Oct 5;326(13):1299-1309. doi: 10.1001/jama.2021.13844.
IMPORTANCE: Assessing the scope of acute medication harms to patients should include both therapeutic and nontherapeutic medication use. OBJECTIVE: To describe the characteristics of emergency department (ED) visits for acute harms from both therapeutic and nontherapeutic medication use in the US. DESIGN, SETTING, AND PARTICIPANTS: Active, nationally representative, public health surveillance based on patient visits to 60 EDs in the US participating in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project from 2017 through 2019. EXPOSURES: Medications implicated in ED visits, with visits attributed to medication harms (adverse events) based on the clinicians' diagnoses and supporting data documented in the medical record. MAIN OUTCOMES AND MEASURES: Nationally weighted estimates of ED visits and subsequent hospitalizations for medication harms. RESULTS: Based on 96 925 cases (mean patient age, 49 years; 55% female), there were an estimated 6.1 (95% CI, 4.8-7.5) ED visits for medication harms per 1000 population annually and 38.6% (95% CI, 35.2%-41.9%) resulted in hospitalization. Population rates of ED visits for medication harms were higher for patients aged 65 years or older than for those younger than 65 years (12.1 vs 5.0 [95% CI, 7.4-16.8 vs 4.1-5.8] per 1000 population). Overall, an estimated 69.1% (95% CI, 63.6%-74.7%) of ED visits for medication harms involved therapeutic medication use, but among patients younger than 45 years, an estimated 52.5% (95% CI, 48.1%-56.8%) of visits for medication harms involved nontherapeutic use. The proportions of ED visits for medication harms involving therapeutic use were lowest for barbiturates (6.3%), benzodiazepines (11.1%), nonopioid analgesics (15.7%), and antihistamines (21.8%). By age group, the most frequent medication types and intents of use associated with ED visits for medication harms were therapeutic use of anticoagulants (4.5 [95% CI, 2.3-6.7] per 1000 population) and diabetes agents (1.8 [95% CI, 1.3-2.3] per 1000 population) for patients aged 65 years and older; therapeutic use of diabetes agents (0.8 [95% CI, 0.5-1.0] per 1000 population) for patients aged 45 to 64 years; nontherapeutic use of benzodiazepines (1.0 [95% CI, 0.7-1.3] per 1000 population) for patients aged 25 to 44 years; and unsupervised medication exposures (2.2 [95% CI, 1.8-2.7] per 1000 population) and therapeutic use of antibiotics (1.4 [95% CI, 1.0-1.8] per 1000 population) for children younger than 5 years. CONCLUSIONS AND RELEVANCE: According to data from 60 nationally representative US emergency departments, visits attributed to medication harms in 2017-2019 were frequent, with variation in products and intent of use by age.
重要性:评估急性药物危害的范围应包括治疗性和非治疗性药物使用。 目的:描述美国急诊部(ED)因治疗性和非治疗性药物使用而导致的急性药物危害就诊的特点。 设计、地点和参与者:基于美国 60 个急诊部的患者就诊情况进行的主动、全国代表性、公共卫生监测,这些急诊部参与了国家电子伤害监测系统-合作药物不良事件监测项目,时间为 2017 年至 2019 年。 暴露情况:与药物危害相关的药物,根据临床医生的诊断和病历中记录的支持数据,将就诊归因于药物危害(不良事件)。 主要结果和措施:全国加权估计的因药物危害而就诊的 ED 就诊人数和随后的住院人数。 结果:根据 96925 例病例(平均患者年龄 49 岁;55%为女性),每年每 1000 人口中有 6.1 例(95%CI,4.8-7.5)因药物危害而就诊 ED,其中 38.6%(95%CI,35.2%-41.9%)需要住院治疗。65 岁及以上患者因药物危害就诊 ED 的人口率高于 65 岁以下患者(每 1000 人口分别为 12.1 比 5.0 [95%CI,7.4-16.8 比 4.1-5.8])。总体而言,估计有 69.1%(95%CI,63.6%-74.7%)的因药物危害就诊 ED 的情况涉及治疗性药物使用,但在 45 岁以下的患者中,估计有 52.5%(95%CI,48.1%-56.8%)的因药物危害就诊 ED 的情况涉及非治疗性药物使用。涉及治疗性药物使用的 ED 就诊中,药物危害最常见的药物类型和使用意图是使用抗凝剂(每 1000 人口 4.5 [95%CI,2.3-6.7])和糖尿病药物(每 1000 人口 1.8 [95%CI,1.3-2.3]),65 岁及以上的患者;65 岁及以上的患者使用糖尿病药物(每 1000 人口 0.8 [95%CI,0.5-1.0]);45 至 64 岁的患者使用糖尿病药物(每 1000 人口 0.8 [95%CI,0.5-1.0]);25 至 44 岁的患者使用苯二氮䓬类药物(每 1000 人口 1.0 [95%CI,0.7-1.3]);5 岁以下儿童使用未经监督的药物暴露(每 1000 人口 2.2 [95%CI,1.8-2.7])和抗生素(每 1000 人口 1.4 [95%CI,1.0-1.8])。 结论和相关性:根据来自 60 个具有全国代表性的美国急诊部的数据,2017-2019 年归因于药物危害的就诊情况频繁,不同年龄的产品和使用意图存在差异。
Am J Prev Med. 2019-3-6
JAMA Psychiatry. 2014-9
Pharmacoepidemiol Drug Saf. 2022-2
J Pediatric Infect Dis Soc. 2019-11-6
J Pediatr Pharmacol Ther. 2025-8
J Med Toxicol. 2025-6-19
Nurs Clin North Am. 2025-6
Front Digit Health. 2025-3-28
J Am Heart Assoc. 2020-7-7
J Gen Intern Med. 2020-1
Am J Prev Med. 2019-4-17
Am J Public Health. 2019-3-21
Am J Prev Med. 2019-3-6
Diabetes Care. 2019-1
Diabetes Care. 2019-1
Diabetes Res Clin Pract. 2017-11